Divya Janardhanan
Pain Medicine · Houston, TXNPI 1043666423
Payments from drug & device makers
Across 238 payments — averaging $28.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Boston Scientific$1K
- Painteq LLC$849
- Collegium Pharmaceutical, Inc.$675
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$438
- Medtronic$422
- plus $2K from 24 others
What the payments were for
- Consulting fees$1252%
- Travel & lodging$1492%
- Food & beverage$6,52296%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 42 | $1,370 |
| Boston Scientific | 20 | $1,012 |
| Painteq LLC | 33 | $849 |
| Collegium Pharmaceutical, Inc. | 37 | $675 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $438 |
| Medtronic(2 entities) | 9 | $422 |
| Nalu Medical, Inc. | 23 | $408 |
| Nevro Corp. | 4 | $311 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $204 |
| Curonix LLC | 4 | $198 |
| AbbVie | 8 | $174 |
| Vertos Medical, Inc. | 2 | $162 |
| Biotronik NRO, Inc. | 3 | $81 |
| Vertex | 2 | $57 |
| SPR Therapeutics, Inc | 3 | $55 |
| GRT US Holding, Inc. | 2 | $52 |
| Averitas Pharma Inc. | 3 | $46 |
| Arbor Pharmaceuticals, Inc. | 3 | $39 |
| Valinor Pharma, LLC | 2 | $29 |
| Stryker | 1 | $27 |
| Bioventus LLC | 1 | $26 |
| Saluda Medical Americas, Inc. | 1 | $22 |
| Amgen | 1 | $22 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| Avanos Medical | 1 | $19 |
| IBSA Pharma Inc. | 1 | $18 |
| Biodelivery Sciences International, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| MML US, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$484
- PAINTEQ$298
- mild Device Kit$148
- V-LOC 180$141
- WAVEWRITER ALPHA$135
- Nalu Neurostimulation System$125
- PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A$123
- SPECTRA WAVEWRITER$122
- WaveWriter Alpha Prime 16$121
- Senza Spinal Cord Stimulation System$116
- Proclaim IPG$116
- NURTEC ODT$112
- GENERAL - THERAPIES$109
How this compares
$6,796 in reported general payments places this provider in the 65th percentile of 583 pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 84 | $55,311 |
| Buprenorphine | 154 | $37,270 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,030 | $30,768 |
| LinzessLinaclotide | 23 | $12,692 |
| Lidocaine | 91 | $11,952 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 264 | $10,218 |
| MovantikNaloxegol Oxalate | 22 | $9,005 |
| Gabapentin | 515 | $6,089 |
| Pregabalin | 289 | $5,976 |
| Diclofenac Sodium | 74 | $3,528 |
| Tizanidine Hcl | 240 | $2,638 |
| Cyclobenzaprine Hcl | 228 | $2,503 |
| Naloxone Hcl | 40 | $2,375 |
| Methocarbamol | 154 | $2,207 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 33 | $1,926 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $675 | $55,31184 claims |
| AbbVieLinzess | $174 | $12,69223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 583 pain medicine providers in Texas.
Other pain medicine in Houston
- Mitchell EngleHouston$1.5M
- Daniel PakHouston$460K
- David LeimanHouston$281K
- Grant ChenHouston$175K
- Gunjan PatelHouston$166K
- Jaideep MehtaHouston$161K
- Mayur KanjiaHouston$46K
- Baominh VinhHouston$44K
- Matthew ChungHouston$26K
- Aaron CalodneyTyler$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.